PHI with Chronic active hepatitis
How does this condition affect your private health insurance?
Chronic active hepatitis (CAH) is a persistent liver inflammation marked by ongoing liver cell damage and fibrosis, potentially progressing to cirrhosis and liver failure. It can stem from autoimmune attacks on liver cells or chronic viral infections like hepatitis B or C. Common symptoms include fatigue, jaundice, and abdominal pain. Diagnosis involves blood tests and liver biopsy. Without effective management, CAH causes irreversible liver damage, impacting quality of life and lifespan. Treatment, often with immunosuppressants or antivirals, aims to control inflammation and prevent disease progression, but often requires long-term commitment.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several weeks to months, often insidious onset.
Duration of Illness (Lifetime)
Lifelong, chronic disease without full cure, though management is possible.
Cost of Treatment (Initial)
High (initial diagnostics, biopsy, medication: several thousand to tens of thousands of Euros/Dollars).
Cost of Treatment (Lifetime)
Very high (lifelong medication, regular monitoring, potential for transplant: tens to hundreds of thousands of Euros/Dollars or more).
Mortality Rate
Moderate to high without adequate treatment (due to cirrhosis, liver failure, HCC); significantly reduced with effective management but remains a risk.
Risk of Secondary Damages
Very high (cirrhosis, liver failure, hepatocellular carcinoma, portal hypertension, encephalopathy, variceal bleeding).
Probability of Full Recovery
Low (remission possible for autoimmune forms but often requires lifelong maintenance; viral forms may be controlled or cleared with specific therapies, but prior liver damage might persist).
Underlying Disease Risk
Moderate to high (other autoimmune diseases for autoimmune hepatitis; co-infections for viral hepatitis; metabolic syndrome can exacerbate liver disease).